BPMC
Income statement / Annual
Last year (2024), Blueprint Medicines Corporation's total revenue was $508.82 M,
an increase of 104.04% from the previous year.
In 2024, Blueprint Medicines Corporation's net income was -$67.09 M.
See Blueprint Medicines Corporation,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$508.82 M |
$249.38 M |
$204.04 M |
$180.08 M |
$793.74 M |
$66.51 M |
$44.52 M |
$21.43 M |
$27.77 M |
$11.40 M |
Cost of Revenue |
$20.16 M
|
$12.80 M
|
$17.81 M
|
$17.93 M
|
$425,000.00
|
$0.00
|
$243.62 M
|
$144.69 M
|
$81.13 M
|
$48.59 M
|
Gross Profit |
$488.66 M
|
$236.58 M
|
$186.22 M
|
$162.15 M
|
$793.31 M
|
$66.51 M
|
-$199.10 M
|
-$123.26 M
|
-$53.36 M
|
-$37.19 M
|
Gross Profit Ratio |
0.96
|
0.95
|
0.91
|
0.9
|
1
|
1
|
-4.47
|
-5.75
|
-1.92
|
-3.26
|
Research and Development Expenses |
$341.43 M
|
$427.72 M
|
$477.42 M
|
$601.03 M
|
$326.86 M
|
$331.45 M
|
$243.62 M
|
$144.69 M
|
$81.13 M
|
$48.59 M
|
General & Administrative Expenses |
$262.67 M
|
$278.24 M
|
$219.27 M
|
$181.79 M
|
$148.34 M
|
$96.39 M
|
$47.93 M
|
$27.99 M
|
$19.22 M
|
$14.46 M
|
Selling & Marketing Expenses |
$96.60 M
|
$16.90 M
|
$18.10 M
|
$13.50 M
|
$9.40 M
|
$3.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$359.27 M
|
$295.14 M
|
$237.37 M
|
$195.29 M
|
$157.74 M
|
$96.39 M
|
$47.93 M
|
$27.99 M
|
$19.22 M
|
$14.46 M
|
Other Expenses |
$0.00
|
$0.00
|
$8.95 M
|
$7.80 M
|
-$366,000.00
|
-$100,000.00
|
$10.46 M
|
$3.35 M
|
$551,000.00
|
-$429,000.00
|
Operating Expenses |
$700.71 M
|
$722.86 M
|
$723.74 M
|
$804.13 M
|
$484.60 M
|
$427.84 M
|
$291.55 M
|
$172.67 M
|
$100.35 M
|
$63.04 M
|
Cost And Expenses |
$720.87 M
|
$735.66 M
|
$741.55 M
|
$822.06 M
|
$485.03 M
|
$427.84 M
|
$291.55 M
|
$172.67 M
|
$100.35 M
|
$63.04 M
|
Interest Income |
$40.66 M
|
$0.00
|
$17.75 M
|
$2.39 M
|
$6.60 M
|
$13.73 M
|
$10.64 M
|
$3.43 M
|
$0.00
|
$0.00
|
Interest Expense |
$68.81 M
|
$0.00
|
$16.77 M
|
$0.00
|
$0.00
|
$13.73 M
|
$73,000.00
|
$221,000.00
|
$469,000.00
|
$696,000.00
|
Depreciation & Amortization |
$16.29 M
|
$11.67 M
|
$20.10 M
|
$12.79 M
|
$12.35 M
|
$10.25 M
|
$4.25 M
|
$1.58 M
|
$1.58 M
|
$948,000.00
|
EBITDA |
-$212.04 M |
-$470.36 M |
-$515.42 M |
-$628.30 M |
$308.71 M |
-$356.07 M |
-$242.78 M |
-$149.67 M |
-$70.44 M |
-$51.13 M |
EBITDA Ratio |
-0.42
|
-1.89
|
-2.63
|
-3.56
|
0.39
|
-5.43
|
-5.31
|
-6.9
|
-2.59
|
-4.57
|
Operating Income Ratio |
-0.42
|
-1.95
|
-2.69
|
-3.6
|
0.38
|
-5.51
|
-5.55
|
-6.98
|
-2.65
|
-4.65
|
Total Other Income/Expenses Net |
$146.18 M
|
-$19.74 M
|
-$14.76 M
|
$897,000.00
|
$6.23 M
|
$13.63 M
|
$10.39 M
|
$3.13 M
|
$82,000.00
|
-$1.13 M
|
Income Before Tax |
-$65.86 M
|
-$506.02 M
|
-$552.28 M
|
-$641.08 M
|
$314.94 M
|
-$347.69 M
|
-$236.64 M
|
-$148.12 M
|
-$72.50 M
|
-$52.77 M
|
Income Before Tax Ratio |
-0.13
|
-2.03
|
-2.71
|
-3.56
|
0.4
|
-5.23
|
-5.32
|
-6.91
|
-2.61
|
-4.63
|
Income Tax Expense |
$1.23 M
|
$968,000.00
|
$5.24 M
|
$3.00 M
|
$1.06 M
|
-$18.99 M
|
$10.46 M
|
$1.99 M
|
-$562,000.00
|
-$681,000.00
|
Net Income |
-$67.09 M
|
-$506.98 M
|
-$557.52 M
|
-$644.09 M
|
$313.88 M
|
-$328.70 M
|
-$236.64 M
|
-$148.12 M
|
-$72.50 M
|
-$52.77 M
|
Net Income Ratio |
-0.13
|
-2.03
|
-2.73
|
-3.58
|
0.4
|
-4.94
|
-5.32
|
-6.91
|
-2.61
|
-4.63
|
EPS |
-1.07 |
-8.37 |
-9.35 |
-11.01 |
5.76 |
-6.87 |
-5.39 |
-3.92 |
-2.64 |
-2.89 |
EPS Diluted |
-1.07 |
-8.37 |
-9.35 |
-11.01 |
5.59 |
-6.87 |
-5.39 |
-3.92 |
-2.64 |
-2.89 |
Weighted Average Shares Out |
$62.86 M
|
$60.56 M
|
$59.64 M
|
$58.52 M
|
$54.53 M
|
$47.83 M
|
$43.87 M
|
$37.79 M
|
$27.49 M
|
$18.24 M
|
Weighted Average Shares Out Diluted |
$62.86 M
|
$60.56 M
|
$59.64 M
|
$58.52 M
|
$56.17 M
|
$47.83 M
|
$43.87 M
|
$37.79 M
|
$27.49 M
|
$18.24 M
|
Link |
|
|
|
|
|
|
|
|
|
|